Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2000
05/04/2000WO2000024707A1 Substituted phenyl derivatives, their preparation and use
05/04/2000WO2000024426A1 Ribozymes used as prodrugs
05/04/2000WO2000024415A2 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
05/04/2000WO2000024408A1 Method for killing tumor and tumor associated endothelial cells using adenoviral mutants
05/04/2000WO2000024405A1 Compounds and their therapeutic use with diabetic complications
05/04/2000WO2000024395A1 New use of glutamate antagonists for the treatment of cancer
05/04/2000WO2000024394A1 Antitumor chrysene derivatives
05/04/2000WO2000024393A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
05/04/2000WO2000024391A2 Conductance of improperly folded proteins through the secretory pathway
05/04/2000WO2000024361A2 Bis(haloethyl)aminobenzene derivatives
05/04/2000WO2000024360A2 Preparation and use of solidified oils
05/04/2000WO2000012741A3 Inducible expression system
05/04/2000WO2000012139B1 Hypoxia regulated genes
05/04/2000WO2000006730A3 Human cytoskeletal proteins
05/04/2000WO2000006703A3 Inhibition of graft versus host disease
05/04/2000WO2000006204A3 Genetically engineered cells and tissues
05/04/2000WO2000006187A3 Modulation of apoptosis
05/04/2000WO2000004910A3 Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
05/04/2000WO2000002917A3 Compounds and methods for modulating cadherin-mediated functions
05/04/2000WO2000002897B1 Delta cleavage products and methods based thereon
05/04/2000WO2000002544A3 Use of piperine for treating skin pigmentation disorders
05/04/2000WO1999067283A8 Two-kinase domain mitogen- and stress-activated protein kinases and uses thereof
05/04/2000WO1999062315A3 Method for altering the activity of proteins of the pka signaling pathway
05/04/2000WO1999054286A3 Btk inhibitors and methods for their identification and use
05/04/2000WO1999043672A9 Inhibitors of phospholipase a2
05/04/2000DE19954040A1 Use of phenol derivatives, e.g. thymol, as prostaglandin antagonists and antiproliferative agents for treating tumors
05/04/2000DE19850131A1 Chromenon- und Chromanonderivate Chromenon- and chromanone
05/04/2000CA2349211A1 Prv-1 gene and the use thereof
05/04/2000CA2348844A1 Compounds and their therapeutic use with diabetic complications
05/04/2000CA2348835A1 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
05/04/2000CA2348833A1 Human phospholipases
05/04/2000CA2348634A1 Methods for killing tumor and tumor associated endothelial cells using adenoviral mutants
05/04/2000CA2348529A1 Conductance of improperly folded proteins through the secretory pathway
05/04/2000CA2348430A1 Ovary-specific genes and proteins
05/04/2000CA2348046A1 Lysine-rich statherin protein
05/04/2000CA2347993A1 Method for producing in vivo proteins chemically diversified by incorporating non-standard amino acids
05/04/2000CA2347982A1 Prostaglandin endoperoxide h synthase biosynthesis inhibitors
05/04/2000CA2347365A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
05/04/2000CA2347294A1 Novel g protein coupled receptor protein, dna and its ligand
05/04/2000CA2346990A1 Serine protease inhibitor
05/04/2000CA2346976A1 Chelating agents for radioimmunotherapy
05/04/2000CA2346873A1 Antitumor chrysene derivatives
05/04/2000CA2346820A1 Preparation and use of solidified oils
05/04/2000CA2344207A1 Biological material for preparing pharmaceutical compositions for treating mammals
05/04/2000CA2342626A1 Substituted phenyl derivatives, their preparation and use
05/04/2000CA2249648A1 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
05/03/2000EP0997476A2 Antibodies to a mammalian Langerhans cell antigen and their uses
05/03/2000EP0997473A1 Natural antitumor or antiviral substances and use of the same
05/03/2000EP0997153A1 Formulations for lipophilic compounds
05/03/2000EP0997152A1 Remedies for lymphocytic tumors
05/03/2000EP0997145A1 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
05/03/2000EP0996857A2 Cancer associated nucleic acids and polypeptides
05/03/2000EP0996733A1 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase from human
05/03/2000EP0996726A1 T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
05/03/2000EP0996725A1 Human nk-3 related prostate specific gene-1
05/03/2000EP0996723A1 Human phosphatidylinositol transfer protein gamma
05/03/2000EP0996710A1 Component of bromelain
05/03/2000EP0996636A1 The ha-1 antigen
05/03/2000EP0996634A1 Crystal of sm3 antibody (fragment) and recognizing epitope, its preparation, encoded data storage medium containing its coordinates and its diagnostical or medical use
05/03/2000EP0996632A1 Angiostatin fragments and method of use
05/03/2000EP0996630A2 Irs-p53h, human insulin receptor tyrosine kinase substrate
05/03/2000EP0996617A1 Novel compounds
05/03/2000EP0996467A1 Txu-7-pap immunotoxin and use thereof
05/03/2000EP0996455A1 $g(a)-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
05/03/2000EP0996450A2 Method for the treatment of cancer with exochelins of mycobacterium tuberculosis
05/03/2000EP0996441A1 Pharmaceutical compositions of arglabin and arglabin derivatives
05/03/2000EP0996433A1 Methods for treatment of conditions associated with lactosylceramide
05/03/2000EP0812204A4 Codominance-mediated toxins
05/03/2000EP0721465B1 Glutathione s-transferase-activated compounds
05/03/2000EP0560947B1 Trivalent monospecific antigen binding proteins
05/03/2000CN1252101A Component of bromelain
05/03/2000CN1252096A Component of bromelain
05/03/2000CN1252076A Production of antihuman antigen receptors and use thereof
05/03/2000CN1252064A Bicyclic amino acids
05/03/2000CN1251991A Carboxylic acid derivatives, their preparation and use in treating cancer
05/03/2000CN1251770A Medicinal composition for treating anorectal cancer and its preparing process
05/03/2000CN1052009C Platium complex and maligant tumor treating drug containing same
05/03/2000CN1051926C Anti-cancer Chinese drug capsule
05/03/2000CN1051921C Methods of inhibiting imperfect tissue repair
05/02/2000US6057457 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
05/02/2000US6057453 Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
05/02/2000US6057450 Derivatives of pyroglutaminic acid preparation process and applications
05/02/2000US6057440 Process for preparing bis-indoly macrocycles
05/02/2000US6057437 Antisense nucleic acid compounds inhibiting vascular endothelial growth factor
05/02/2000US6057435 Nucleic acid coding for polypeptide which binds to receptor tyrosine kinase containing immunoglobulin-like and epidermal growth factor homology domains expressed in vascular endothelial cells; diagnosis/imaging; angiogenesis inhibition
05/02/2000US6057428 Variants of vascular endothelial cell growth factor
05/02/2000US6057422 Antagonistic analogs of GH-RH inhibiting IGF-I and -II
05/02/2000US6057361 Formulations and methods of reducing toxicity of antineoplastic agents
05/02/2000US6057338 Useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy
05/02/2000US6057336 Lactam metalloprotease inhibitors
05/02/2000US6057329 Inhibitors of the protein tyrosine kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases
05/02/2000US6057326 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
05/02/2000US6057300 Introducing expression vector comprising gene encoding p21 and expression vector comprising second gene encoding immunotherapeutic agent, genetic therapeutic, cytokine or prodrug converting enzyme to treat restenosis
05/02/2000US6057292 Method for inhibiting growth hormone action
05/02/2000US6057156 Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
05/02/2000US6057132 Nucleotide sequences encoding apoptosis associated Bbk protein
05/02/2000US6057128 MU-1, member of the cytokine receptor family
05/02/2000US6057122 Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
05/02/2000US6057115 Process for producing GM2 specific antibodies
05/02/2000US6057112 Ubiquitin conjugation proteins
1 ... 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 ... 2211